Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer

NCT04246203 is registered in ClinicalTrials.gov with Ludwig-Maximilians - University of Munich as lead sponsor.

NCT NCT04246203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04246203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer
Lead sponsor
Ludwig-Maximilians - University of Munich
Phase
Observational
Overall status
Active, not recruiting
Start date
December 12, 2021
Completion date
December 1, 2026
Enrollment
200 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer